MLabs to be renamed Michigan Medicine Laboratories

Reference laboratory services available through Michigan Medicine now have a new name: Michigan Medicine Laboratories.

MLabs offers NGS to detect PIK3CA mutation targeted by New Metastatic Breast Cancer Treatment

Many patients living with metastatic breast cancer (mBS) now have a new treatment option.

In May 2019, the FDA approved a new targeted therapy, alpelisib (Piqray®). An oral medication intended to be used in combination with fulvestrant (Faslodex®), Piqray® is...

MLabs Approved to Participate in NCI-MATCH Clinical Trial

MLabs, and the Department of Pathology laboratories at Michigan Medicine, recognized leaders for advanced diagnostic testing, are now participating in the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial. 

MLabs NGS Panels Detects NTRK Fusion Genes in Select Solid Tumor Patients for FDA-approved Vitrakvi® (larotrectinib) Therapy

MLabs next-generation sequencing (NGS) offerings include Solid Tumor, Lung Cancer, Colorectal Cancer, and Melanoma NGS Panels. These NGS tests target 50 genes to detect substitution and insertion/deletion mutations (35 genes), gene amplifications (19 genes), and gene fusions (21 genes) including NTRK gene fusions...

USCAP 2018 CONFERENCE

MLabs will be exhibiting at the USCAP 2018 Conference held in Vancouver, BC, Canada. You can visit MLabs booth #506 during the exhibit hours...